CD262 (DR5) Monoclonal Antibody (MD5-1), PE, eBioscience™ | Invitrogen 12-5883-82 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

CD262 (DR5) Monoclonal Antibody (MD5-1), PE, eBioscience™

catalog :

12-5883-82

quantity :

100 µg

price :

US 309.00

clonality :

monoclonal

host :

hamsters

conjugate :

clone name :

MD5-1

reactivity :

mouse

application :

flow cytometry

more info or order :

Invitrogen product webpage

citations: 15

Published Application/Species/Sample/Dilution	Reference
flow cytometry; mouse; loading ...; fig s3g	Pishesha N, Bilate A, Wibowo M, Huang N, Li Z, Deshycka R, et al. Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease. Proc Natl Acad Sci U S A. 2017;114:3157-3162 pubmed publisher
flow cytometry; mouse	Zheng S, Jiang J, Shen H, Chen Y. Reduced apoptosis and ameliorated listeriosis in TRAIL-null mice. J Immunol. 2004;173:5652-8 pubmed
	Estornes Y, Dondelinger Y, Weber K, Bruggeman I, Peall A, MacFarlane M, et al. N-glycosylation of mouse TRAIL-R restrains TRAIL-induced apoptosis. Cell Death Dis. 2018;9:494 pubmed publisher
	Werner L, Kler J, Gressett M, Riegert M, Werner L, Heinze C, et al. Transcriptional-mediated effects of radiation on the expression of immune susceptibility markers in melanoma. Radiother Oncol. 2017;124:418-426 pubmed publisher
	Dang V, Tanabe K, Tanaka Y, Tokumoto N, Misumi T, Saeki Y, et al. Fasting enhances TRAIL-mediated liver natural killer cell activity via HSP70 upregulation. PLoS ONE. 2014;9:e110748 pubmed publisher
	Iyori M, Zhang T, Pantel H, Gagne B, Sentman C. TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells. J Immunol. 2011;187:3087-95 pubmed publisher
	Wolkers M, Bensinger S, Green D, Schoenberger S, Janssen E. Interleukin-2 rescues helpless effector CD8+ T cells by diminishing the susceptibility to TRAIL mediated death. Immunol Lett. 2011;139:25-32 pubmed publisher
	Coureuil M, Ugolin N, Tavernier M, Chevillard S, Barroca V, Fouchet P, et al. Puma and Trail/Dr5 pathways control radiation-induced apoptosis in distinct populations of testicular progenitors. PLoS ONE. 2010;5:e12134 pubmed publisher
	Haynes N, Hawkins E, Li M, McLaughlin N, Hämmerling G, Schwendener R, et al. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J Immunol. 2010;185:532-41 pubmed publisher
	Mizrahi K, Stein J, Pearl Yafe M, Kaplan O, Yaniv I, Askenasy N. Regulatory functions of TRAIL in hematopoietic progenitors: human umbilical cord blood and murine bone marrow transplantation. Leukemia. 2010;24:1325-34 pubmed publisher
	Vogler M, Walczak H, Stadel D, Haas T, Genze F, Jovanovic M, et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res. 2009;69:2425-34 pubmed publisher
	Brincks E, Katewa A, Kucaba T, Griffith T, Legge K. CD8 T cells utilize TRAIL to control influenza virus infection. J Immunol. 2008;181:4918-25 pubmed
	Tseng C, Monie A, Trimble C, Alvarez R, Huh W, Buchsbaum D, et al. Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine. 2008;26:4314-9 pubmed publisher
	Treese C, Mittag A, Lange F, Tarnok A, Loesche A, Emmrich F, et al. Characterization of fibroblasts responsible for cartilage destruction in arthritis. Cytometry A. 2008;73:351-60 pubmed publisher
	Khan T, Stauffer J, Williams R, Hixon J, Salcedo R, Lincoln E, et al. Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors. J Immunol. 2006;176:6302-12 pubmed

product information

Product Type :

Antibody

Product Name :

CD262 (DR5) Monoclonal Antibody (MD5-1), PE, eBioscience™

Catalog # :

12-5883-82

Quantity :

100 µg

Price :

US 309.00

Clonality :

Monoclonal

Purity :

Affinity chromatography

Host :

Armenian Hamster

Reactivity :

Mouse

Applications :

Flow Cytometry: 0.25 µg/test

Species :

Mouse

Clone :

MD5-1

Isotype :

IgG

Storage :

4° C, store in dark, DO NOT FREEZE!

Description :

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 0.25 µg/test

Aliases :

apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; Dr5; dr-5; Fas-like protein; KILLER; KILLER/DR5; KILLER/DR5 TRAIL death-inducing receptor; Ly98; MK; p53-regulated DNA damage-inducible cell death receptor(killer); sCD262; soluble CD262; TNF receptor superfamily member 10b; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TRAIL receptor 2; TRAILR2; TRAIL-R2; TRICK2; TRICK2A; TRICK2B; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; UNQ160/PRO186; ZTNFR9

more info or order :

Invitrogen product webpage